Quotient Therapeutics Appoints Andrew Bayliffe as Chief Development Officer to Advance Somatic Genomics Platform
Key Insights
Quotient Therapeutics (search) has appointed Andrew Bayliffe, PhD, as Chief Development Officer, bringing over 25 years of biopharmaceutical leadership experience to the somatic genomics company.
Bayliffe previously spent 20 years at GlaxoSmithKline leading drug discovery and development programs, and served as Chief Scientific Officer at Marengo Therapeutics (search) for over five years.
The appointment comes at a pivotal time as Quotient looks to translate its somatic genomics findings into breakthrough medicines through its internal and partnered programs.
Quotient Therapeutics (search), a Cambridge-based company pioneering somatic genomics to inform breakthrough medicines, announced the appointment of Andrew (Andy) Bayliffe, PhD, as Chief Development Officer. The strategic hire brings over 25 years of leadership experience in the biopharmaceutical industry, with expertise spanning discovery and development of small molecule and antibody therapeutics (search) across a broad range of disease areas.
"Andy brings a depth of drug development expertise across modalities and therapeutic areas, joining at a pivotal time as we look to translate our somatic genomics findings into meaningful medicines for patients," said Rahul Kakkar, MD, Chief Executive Officer of Quotient. "His leadership will be instrumental in executing on our internal and partnered programs, and we are delighted to welcome him to the team."
Extensive Industry Experience
Bayliffe's career spans pharmaceutical, biotech and venture capital roles. During his 20-year tenure at GlaxoSmithKline Pharmaceuticals, he led the discovery and development of numerous drug programs through early and late phases across a broad range of therapy areas, while developing deep expertise in the clinical pharmacology of both small and large molecules.
More recently, as a Venture Partner at Apple Tree Partners (search) venture capital firm, Bayliffe co-founded Marengo Therapeutics (search) where he served as Chief Scientific Officer. In this role, he led the discovery of several novel TCR (search)-targeted antibody platforms for treating autoimmune and oncology diseases (search). During more than five years as CSO at Marengo, he led the development of a diverse pipeline of wholly owned and partnered programs in addition to defining the translational pharmacology of lead molecules in Phase 1/2 clinical trials.
Strategic Vision for Somatic Genomics
"Through the discovery of novel drug targets, Quotient has a unique opportunity to transform standards of care across a broad spectrum of diseases," Bayliffe said. "I look forward to joining this innovative team and ensuring our Somatic Genomics technology enables the development of treatments for patients in need."
Bayliffe has a successful track record collaborating with basic and clinical academics, funding agencies, and regulatory authorities, and continues to publish original research in peer-reviewed journals while contributing to the broader translational science and experimental medicine field through interactions with learned societies and institutions.
About Quotient's Platform
Quotient Therapeutics (search) develops breakthrough medicines informed by natural somatic genetic diversity present in patients. Through its integrated somatic genomics and computational technologies, the company gains unbiased, unprecedented resolution into disease-causal drug targets that it leverages to design and develop first-in-class therapies. The company was founded by Flagship Pioneering (search) in 2022 and is forging a new status quo for biopharma research and development through a broad pipeline of internal and partnered programs.
Bayliffe completed his undergraduate and PhD studies in pharmacology, physiology and molecular biology at Manchester Metropolitan University and Leeds University in the UK.